Review
Infectious Diseases
Kasama Manothummetha, Thanuthong Mongkolkaew, Punyot Tovichayathamrong, Rabhas Boonyawairote, Tanaporn Meejun, Karan Srisurapanont, Kasidis Phongkhun, Anawin Sanguankeo, Pattama Torvorapanit, Chatphatai Moonla, Rongpong Plongla, Olivia S. Kates, Robin K. Avery, Saman Nematollahi, Nitipong Permpalung
Summary: This study summarized the efficacy of ribavirin in treating respiratory syncytial virus infection in patients with hematologic malignancies and hematopoietic stem cell transplant recipients. The results showed that ribavirin use did not significantly affect all-cause mortality and RSV-associated mortality, but it was associated with lower mortality and progression to lower respiratory tract infection in certain subgroups.
CLINICAL MICROBIOLOGY AND INFECTION
(2023)
Article
Immunology
Vera Portillo, Stavroula Masouridi-Levrat, Lena Royston, Sabine Yerly, Manuel Schibler, Maria Mappoura, Sarah Morin, Federica Giannotti, Anne-Claire Mamez, Christian van Delden, Yves Chalandon, Dionysios Neofytos
Summary: Positive CMV serology in allogeneic hematopoietic cell transplant recipients (allo-HCTRs) may be false-positive due to transfusion-associated passive immunity. Reclassifying CMV status can help accurately assess the risk of CMV infection in these patients.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Virology
Xunyan Ye, Obinna P. Iwuchukwu, Vasanthi Avadhanula, Letisha O. Aideyan, Trevor J. McBride, David M. Henke, Kirtida D. Patel, Felipe-Andres Piedra, Laura S. Angelo, Dimpy P. Shah, Roy F. Chemaly, Pedro A. Piedra
Summary: This study found that specific humoral and mucosal RSV antibodies play an important role in viral clearance in HCT recipients naturally infected with RSV, especially in the clearance of different RSV subtypes. The results of this study have implications for antigen selection in the development of RSV vaccines.
Review
Medicine, Research & Experimental
Sofia Tejada, Raquel Martinez-Reviejo, Hanife N. Karakoc, Yolanda Pena-Lopez, Oriol Manuel, Jordi Rello
Summary: This study summarized the efficacy and safety of ribavirin for the treatment of respiratory syncytial virus (RSV) associated lower respiratory tract infections. The results showed that ribavirin is effective in treating RSV-LRTI in patients with hematological diseases, and oral ribavirin is associated with increased viral clearance. However, there is a lack of evidence to support its use in lung transplant recipients.
ADVANCES IN THERAPY
(2022)
Article
Immunology
Anna Apostolopoulou, Cornelius J. Clancy, Abigail Skeel, M. Hong Nguyen
Summary: This study retrospectively reviewed the occurrence of invasive pulmonary aspergillosis (IPA) in solid organ transplant recipients within 90 days of noninfluenza respiratory viral infections. It found that lung and small bowel transplant recipients were more likely to develop IPA, with cumulative prednisone doses >140 mg within 7 days and pneumonia at the time of noninfluenza respiratory viral infection identified as independent risk factors. Mortality at 180 days following noninfluenza respiratory viral infection was also higher among IPA patients.
OPEN FORUM INFECTIOUS DISEASES
(2021)
Article
Virology
Chikara Ogimi, Hu Xie, Alpana Waghmare, Keith R. Jerome, Wendy M. Leisenring, Filippo Milano, Janet A. Englund, Michael Boeckh
Summary: This study evaluated whether the initial viral burden of upper respiratory tract infection (URTI) viruses predicts the risk of progression to lower respiratory tract infection (LRTI) in adult allogeneic hematopoietic cell transplant (HCT) recipients. The study found that higher viral burden was associated with an increased risk of progression to LRTI for influenza, but not for other viruses.
JOURNAL OF CLINICAL VIROLOGY
(2022)
Article
Immunology
Jose Luis Pinana, Alienor Xhaard, Gloria Tridello, Jakob Passweg, Anne Kozijn, Nicola Polverelli, Inmaculada Heras, Ariadna Perez, Jaime Sanz, Dagmar Berghuis, Lourdes Vazquez, Maria Suarez-Lledo, Maija Itala-Remes, Tulay Ozcelik, Isabel Iturrate Basaran, Musa Karakukcu, Mohsen Al Zahrani, Goda Choi, Marian Angeles Cuesta Casas, Montserrat Batlle Massana, Amato Viviana, Nicole Blijlevens, Arnold Ganser, Baris Kuskonmaz, Helene Labussiere-Wallet, Peter J. Shaw, Zeynep Arzu Yegin, Marta Gonzalez-Vicent, Vanderson Rocha, Alina Ferster, Nina Knelange, David Navarro, Malgorzata Mikulska, Rafael de la Camara, Jan Styczynski
Summary: This study on seasonal HCoVs after allo-HSCT found a high incidence of LRTD and higher mortality in critical cases, with absolute lymphocyte count, corticosteroid use, and ICU admission identified as factors associated with increased mortality in LRTD patients.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Oncology
Kimberley Joanne Hatfield, Oystein Bruserud, Hakon Reikvam
Summary: This study found that the pretransplant lipid profiles can be used for the subclassification of patients and possibly identify those with an increased risk of death due to disease relapse or treatment toxicity. Therapeutic targeting of lipid metabolism should be further explored in these transplant recipients.
Article
Infectious Diseases
Hugo Testaert, Margaux Bouet, Florent Valour, Anne Gigandon, Marie -Edith Lafon, Francois Philit, Agathe Senechal, Jean-Sebastien Casalegno, Elodie Blanchard, Jerome Le Pavec, Florence Ader
Summary: This study analysed the impact of antimicrobial treatments on functional outcomes in adult lung transplant recipients with RSV-confirmed infection. It was found that 28.8% of recipients developed new allograft dysfunction at 3 months post-infection. Ribavirin treatment and azithromycin prophylaxis did not prevent decline in lung function.
CLINICAL MICROBIOLOGY AND INFECTION
(2021)
Article
Immunology
Scott W. Mueller, Tyree H. Kiser, Taylor Morrisette, Martin R. Zamora, Dennis M. Lyu, Jennifer J. Kiser
Summary: Ribavirin may improve outcomes in lung transplant patients with RSV; however, further studies are needed to understand its pharmacokinetics in different respiratory compartments to guide clinical use for respiratory viruses.
TRANSPLANT INFECTIOUS DISEASE
(2021)
Article
Immunology
Armin Rashidi, Jonathan U. Peled, Maryam Ebadi, Tauseef Ur Rehman, Heba Elhusseini, LeeAnn T. Marcello, Hossam Halaweish, Thomas Kaiser, Shernan G. Holtan, Alexander Khoruts, Daniel J. Weisdorf, Christopher Staley
Summary: This study found that the gut microbiota Blautia can prevent neutropenic fever by improving intestinal health. Restoring Blautia may help reduce the incidence of neutropenic fever and related complications.
CLINICAL INFECTIOUS DISEASES
(2022)
Review
Immunology
Auke de Zwart, Annelies Riezebos-Brilman, Gerton Lunter, Judith Vonk, Allan R. Glanville, Jens Gottlieb, Nitipong Permpalung, Huib Kerstjens, Jan-Willem Alffenaar, Erik Verschuuren
Summary: In lung transplant recipients, RSV/PIV/hMPV infections are associated with a high incidence of chronic allograft dysfunction. However, current treatment options are limited. There is an urgent need for high-quality studies to provide better treatment options for these infections.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Virology
Sebastien Barral, Aline Mamin, Carole Dantin, Stavroula Masouridi-Levrat, Yves Chalandon, Laurent Kaiser, Diem-Lan Vu
Summary: This retrospective observational study found that rhinovirus infections are the most common in allo-HSCT patients, including pre-transplant infections. However, the mortality rate due to pre-transplant RVIs is low.
Article
Immunology
Bryan O. Nyawanda, Nancy A. Otieno, Michael O. Otieno, Gideon O. Emukule, Godfrey Bigogo, Clayton O. Onyango, Shirley Lidechi, Jeremiah Nyaundi, Gayle E. Langley, Marc-Alain Widdowson, Sandra S. Chaves
Summary: This study found that in western Kenya, HIV infection may increase the risk of pregnant women contracting respiratory syncytial virus (RSV), while the infection rate in infants is not affected by HIV exposure or prematurity.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Biophysics
Rosalia De la Puerta, Juan Montoro, Carla Aznar, Ignacio Lorenzo, Eva Maria Gonzalez-Barbera, Aitana Balaguer-Rosello, Manuel Guerreiro, Lara Dominguez, Miguel Salavert, Cristobal Aguilar, Javier de la Rubia, Jaime Sanz, Maria Dolores Gomez, Jose Luis Pinana
Summary: During the SARS-COV-2 pandemic, there was a significant decrease in the circulation of common seasonal respiratory viruses in allo-HSCT recipients. This suggests that prevention measures in the general population are highly effective in reducing the prevalence of CSRV and its complications in immunocompromised patients.
BONE MARROW TRANSPLANTATION
(2021)
